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Abstract  
Antigens expressed on the surface of cancer cells are accessible targets for both 
humoral and cell-mediated immune responses, and are therefore potential candidates 
for vaccine development. Treating surface of live human breast adenocarcinoma cells 
(MCF-7) with trypsin yields a digest that contains 0.7% of total cell protein. Despite 
this difference, the trypsin digest stimulates in cytotoxicity assays anti-tumor response 
which kills 10-40% more cancer cells than those stimulated with cells themselves. 
From these results, we concluded that trypsin digest obtained from live cancer cells 
contains the essential antigens to induce an immune-mediated anti-tumor effect, and 
therefore, is candidate for anti-tumor vaccine development. 
 





Vaccines which use cancer cells as 
a source of these antigens have been 
investigated for more than 20 years, and 
cell-based vaccinations show great 
potential for prevention different types of 
cancers (1). Furthermore, cell-based 
vaccinations have an advantage over other 
immuno-therapies that target only specific 
epitopes since cell-based vaccines can 
recognize multiple native antigens, many 
of which have not been isolated or 
characterized (2). However, there are 
several aspects of cell-based vaccinations 
that require further development. For 
example, while cancer cells provide surface 
antigens that are targets for a desired 
immune response, they also contain a high 
abundance of house-keeping proteins, 
carbohydrates, nucleic acids, and other 
intracellular contents that are ubiquitous in 
mammalian cells. These ubiquitous 
molecules are undesirable for targeting 
immune-based therapies. Another potential 
limitation with cell-based vaccines is the 
difficulty of purifying cells from possible 
dangerous intracellular contaminants such 
as cellular parasites, viruses, toxins and 
prions. Improving these aspects of cell-
based vaccines is essential for improving 





One possible and attractive method 
to improve the development of cancer 
vaccines is to isolate essential targets of 
tumor cells which can be used to develop 
vaccines. The meaningful targets for 
immune responses are mainly domains of 
surface-expressed proteins and 
glycoproteins that are accessible to 
antibodies and cytotoxic immune cells. (5-
7) These targets are also accessible to 
proteases, and therefore they can 
potentially be isolated by proteolytic 
cleavage (8). The antigen profile obtained 
by proteolytic cleavage contains a 
comprehensive set of native antigens that 
can be used to direct immuno-therapeutics 
while minimizing the amount of ubiquitous 
molecules that are not useful targets. 
Improving methods of antigen isolation 
could potentially improve the efficiency 
with which cancer vaccines can be 
developed.  
This work shows that 
proteolytically-cleaved cell surface antigens 
from live tumor cells can be used to 
stimulate immune responses directed 
toward same tumor cells. For this purpose 
the trypsin digest from live human breast 
adenocarcinoma cells (MCF-7) was used to 
stimulate immune-mediated cytotoxic 





































Materials and Methods 
Preparation of lysate and trypsin digest 
from MCF-7 cells 
MCF-7 cells (ATCC) were grown to 75% 
confluence in RPMI-1640 (PanEco, Russia) 
supplemented with 10% fetal bovine serum 
(FBS). The cells were washed 5× with 
Hank’s Balanced Salt Solution (HBSS) and 
trypsin (0.2 µg/mL, activity 15000 U/mg, 
Promega) solution prepared on HBSS was 
added to the cells (40 µL/cm2). Cells were 
incubated at 37 ºC in saturated humidity 
for 20 min. Trypsin solution was collected 
and centrifuged (600 × g for 5 min). The 
resulting supernatant (denoted as trypsin 
digest) contained cell surface protein 
fragments and trypsin. Cell viability after 
treatment with trypsin was determined 
directly in culture flask using the trypan 
blue exclusion method (9). MCF-7 lysate 
was prepared as previously described (10). 
The protein concentration of the lysate and 
trypsin digest was determined with BCA™ 
Protein Assay Kit (Thermo Scientific, USA). 
Preparation of tumor lysate- and trypsin 
digest-loaded DC 
Dendritic cells (DC) were generated as 
described previously (11). Briefly, fresh 
peripheral blood mononuclear cells (PBMC) 
from healthy donors were isolated by 
Ficoll-Hypaque gradient centrifugation and 
then allowed to adhere to culture flasks for 
1 h. The fraction of non-adherent cells was 
collected and centrifuged. Cell pellets were 
mixed with autologous serum containing 
10% DMSO and stored in liquid nitrogen. 
Cryo-preserved non-adherent PBMC were 
later used as a source of effector cells 
(cytotoxic T lymphocytes, CTL) for 
cytotoxicity assays. The adherent cell 
fraction was harvested and cultured in 
RPMI-1640 supplemented with 10% FBS in 
the presence of 1000 U/mL granulocyte 
macrophage colony-stimulating factor and 
1000 U/mL interleukin-4 (Sigma-Aldrich). 
Six days after culture, either MCF-7 cell 
lysate (final concentration of 270 µg of 
protein/mL), or trypsin digest (2 µg of 
protein/mL) was added to equal volume of 
immature DC. After 3 h of incubation, DC 
were matured with 1000 U/mL of tumor 
necrosis factor-α (Sigma-Aldrich) for 48 h. 
For successive cycles of CTL stimulation, 
aliquots of lysate- or trypsin digest-loaded 
DC were cryo-preserved and thawed as 
needed. The freezing method used was 
described previously (12). 
 
Stimulation of CTL 
Lysate- or trypsin digest-loaded DC (4.5 × 
104) were combined with 9 × 105 
autologous non-adherent PBMC (1:20) in 4 
mL of RPMI-1640 medium supplemented 
with 30 U/mL of clinical grade human 
interleukin-2 (Ronkoleukin, Russia) and 
10% FBS. The culture medium 
supplemented with interleukin-2 was 
replaced every third day. The next portion 
of antigen-loaded DC was added to PBMC 
seven days after stimulation. After next 
five days, the non-adherent PBMC 
containing stimulated CTL were washed by 
centrifugation and used in cytotoxicity 
assays as effector cells.  
Cytotoxicity assay  
MCF-7 cells were seeded at 5 × 103 
cells/well into 48-well culture plates, and 
after 48 h of incubation cultures had 
expanded to 5 × 104 cells/well. Effector CTL 
were then added to MCF-7 cells at specific 
effector:target ratios. At each time point, 
wells were washed to remove CTL, 
attached MCF-7 cells were trypsinized and 
measured for viability by trypan blue 
exclusion. Cell counts were averaged over 
three measurements, and the number of 
surviving MCF-7 cells was plotted against 
time. The killing rate per day per effector 
CTL is derived from the difference in rate 
constants on the log linear plots of MCF-7 
cell growth curves in the presence and 
absence of effector CTL (13).  
Results 
Calculation of dead cells in microscopic 
fields showed that cell death rate does not 
exceed 0.5% by treating cells with trypsin 
for 20 min (Fig. 1). Protein concentration 
was measured in MCF-7 lysate and in 
trypsin digest obtained from the same 
quantity of cancer cells. The cell lysate 
contained 270 µg/mL protein while the 
trypsin digest contained 2 µg/mL. In order 
to test the immunologic properties of the 
trypsin digest, DC were loaded with it and 
used to stimulate normal human CTL in a 
cytotoxicity assay. Unloaded and whole-cell 
lysate-loaded DC were used as controls. 
Visual inspection of target cells during the 
cytotoxicity assay revealed that CTL 
stimulated with trypsin digest-loaded DC 
killed target MCF-7 cells as effectively as 
CTL stimulated with lysate-loaded DC (Fig. 
2c, 2c’,2d, 2d’). Control target cells without 





































unloaded DC showed progressive growth 
(Fig. 2a, 2a’, 2b. 2b’). 
In the cytotoxicity assay, CTL 
stimulated by DC were incubated with 
MCF-7 cell at varying CTL-to-target cells 
ratios and surviving tumor cells were 
counted daily by trypan blue exclusion (Fig. 
3). CTL killed MCF-7 cells in dose-
dependent manner. The CTL:MCF-7 cell 
ratios tested here covered a wide range of 
CTL activity, from low (1:1) to high (8:1). 
At the highest ratio, CTL killed all MCF-7 
cells. The cytotoxic activity of CTL after 
stimulation with DC that were loaded with 
the trypsin digest was better (killed 10-
40% more target cells; p < 0.05) than CTL 
stimulated with DC that were loaded with 
lysate. This phenomenon was observed for 
all CTL:MCF-7 ratios.  
Cytotoxic activity was not observed 
when unstimulated PBMC were incubated 
with MCF-7 cells at two different ratios 
(4:1, 8:1). In these cases, the MCF-7 
proliferated 5 × 105 cells per well after 72 
h. This is identical to MCF-7 cells cultured 
in the absence of CTL altogether (Fig. 3). 
Discussion 
Anti-tumor vaccines are effective 
because molecules on the surface of tumor 
cells are distinct from those presented on 
untransformed cells. Surface antigens are 
excellent targets for immune-mediated 
anti-cancer therapies due to their 
accessibility to antibodies and cytotoxic 
cells. Intracellular antigens are 
sequestered within cells and therefore less 
useful as antigens for vaccination. Using 
proteases to collect tumor-surface-
associated antigens gives promise to 
generating anti-cancer immuno-
therapeutics by exploiting the anti-tumor 
response of the immune system. This 
approach to generate anti-cancer antigens 
makes sense only if treatment of cells with  
 
 
proteases results in low cell death rates. 
This is necessary to avoid contaminating 
the collected surface antigens by the 
intracellular contents released from dead 
cells. Figure 1 shows that selected 
conditions for the cells treatment with 
trypsin results in a cell death rate < 0.5%. 
Thus, treating live cells with proteases 
allows collection of antigenic targets 
directly from cell surface, and prevents 
contamination by undesired intracellular 
content. 
From the results of protein 
concentration measurements, the protein 
content of the trypsin digest is 0.7% from 
the protein content of the cell lysate. The 




Figure 1:  In situ trypan blue staining of 
monolayer MCF-7 cell cultures before (a) and after 
(b) cell treatment with trypsin. Dye stained dead 
cells (see arrow). Images were made by using 







Figure 2:  CTL mediated lysis of MCF-7 cells 
during cytotoxicity assay. 
Target MCF-7 cells were seeded at 5 × 104 cells per 
well in 48-well tissue culture plates, and then 
effector CTL were added at CTL:MCF-7 ratio 4:1. 
On following (a-d) or 3rd (a’-d’) day, target cells 
were carefully washed with HBSS and 
photographed on an inverted phase contrast 
microscope (scale bar: 50 µm). (a, a’) MCF-7 cells 
grown alone. (b, b’) MCF-7 cells incubated with 
CTL that had been stimulated with unloaded DC. 
(c, c’) MCF-7 cells incubated with CTL that had 
been stimulated with lysate-loaded DC. (d, d’) 
MCF-7 cells incubated with CTL that had been 






































be explained in the following manner. 
Proteases only cleave extracellular portions 
of plasma-membrane-associated proteins 
that are accessible to the protease, which 
in total justifies the observed low level of 
proteins in trypsin digest. 
To confirm that trypsin digest 
contains the essential antigens for 
vaccination, the immunogenic properties of  
trypsin digest and cell lysate were 
compared. In an in vitro model of human 
anti-tumor therapies, human CTL were 
incubated with tumor cell targets at 
varying CTL-to-tumor cell ratios. 
Microscopic photographs (Fig. 2) and 
results of cytotoxicity assays (Fig. 3) show 
that DC loaded with the trypsin digest 
stimulated the cytotoxic actions of CTL just 
as effectively as DC loaded with MCF-7 
lysate. Therefore, we assumed that despite  
 
the trypsin digest containing less protein 
than the lysate, it had the same ability to 
induce cytotoxic activity in CTL. This is due 
to the necessary antigens being present in 
the trypsin digest that is free of 
intracellular substances. This is a proof-of-
concept, that the treatment of live tumor 
cells with proteases leads to the release of 
antigenic targets from cells that is 
sufficient to induce anti-tumor immune 
responses in vitro. 
 
Conclusions 
Further characterization of trypsin 
digests, such as the choice of adjuvant and 
schedule, is required for vaccine 
development. However, the diversity of 
native tumor-associated antigens, low 
levels of undesirable antigens, and purity 
regarding dangerous intracellular agents, 
demonstrates the potential for trypsin 
digests as anti-cancer vaccine candidates.  
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